相关实验视频
Updated: Sep 18, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.6K
帕金森病多式疗法对自主和心血管反应的性别差异:试点研究
Franziska Siche-Pantel1, Manfred Mühlenberg2, Rüdiger Buschfort3
1Department of Exercise and Health, Faculty of Science, Institute of Sports Medicine, Paderborn University, Warburger Str. 100, Paderborn, 33098, Germany.
BMC neurology
|June 26, 2025
概括
这项研究在接受康复的帕金森病 (PD) 患者中发现了性别特异性心血管反应. 与男性不同的是,女性在治疗后心率 (HR) 和血压 (BP) 显著变化,这表明定制治疗可能是有益的.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 康复医学 康复医学 康复医学
背景情况:
- 帕金森病 (PD) 呈现出性别特异性差异,并与心血管失调 (CDR) 有关.
- 在接受治疗的PD患者中,标准心率 (HR) 和血压 (BP) 的变化尚未完全理解.
- 像心率变化 (RMSSD) 和皮电活动 (平均EDA) 这样的自主参数可以提供对自主功能的见解.
研究的目的:
- 在多模式住院康复计划期间,研究帕金森病 (PD) 患者的性别特异性心血管和自主反应.
- 为了比较男性和女性治疗前后HR,BP,RMSSD和平均EDA的变化.
主要方法:
- 一项试点研究涉及41名PD患者 (24名男性,17名女性) 接受静止多模式治疗干预 (MTI).
- 测量HR,BP,RMSSD和平均EDA是在基线和MTI后,在卧卧状态下进行的.
- 统计分析包括威尔科克森测试以检测群体内的变化和曼-惠特尼-U测试以检测性别差异.
主要成果:
- 在MTI之前,与基线相比,女性在静止后休息时表现出明显更高的卧底HR和BP.
- 在MTI后,女性在静止后休息时,卧式HR和BP显著下降.
- 男性的HR和BP保持稳定,条件之间没有显著差异. 在两种性别中,RMSSD和平均EDA都是一致的.
结论:
- 对MTI的性别特异性反应突显出需要针对PD心血管症状进行量身定制的治疗管理.
- 在PD患者中,外周心血管变化与自主调节结果没有直接联系.
- 建议对自主性参数进行进一步的研究,以开发针对PD中中枢神经系统机制的向疗法.
相关概念视频
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
Disorders of the Autonomic Nervous System
830
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's...
Raynaud's disease, also known as Raynaud's...
830
Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
Pathophysiology of Cardiac Performance
815
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
815
Drugs Acting on Autonomic Ganglia: Blockers
1.2K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.2K

